Siva Harsha Yedlapati

Siva Harsha Yedlapati

Auto-generated profile, based on publicly available information

Siva Harsha Yedlapati

Department of Internal Medicine, Erie County Medical Center, Buffalo, NY

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2018 in Alcohol and Alcoholism
Verified
Journal Article
Closed access
PDF file
SYSiva Harsha Yedlapati
Siva Harsha Yedlapati
SSScott H Stewart
Scott H Stewart
Hospital readmissions serve as a major benchmark for the quality of care and alcohol withdrawal (AW) may lead to multiple hospitalizations and readmissions. We sought to evaluate readmission rates and predictors of having AW-related readmissions in a nationally representative sample. In a nationally representative sample, AW readmission within 30 days and multiple readmissions during the year were high and were particularly predicted by discharge against medical advice (AMA), comorbid psychosis, comorbid depression, poor socioeconomic status, comorbid drug abuse and alcohol-related medical disease. Subjects from the 2013 Nationwide Readmissions Database (NRD) with AW as a primary or secondary diagnosis. Cross-sectional and retrospective analyses were performed using regression methods appropriate for the NRD complex sampling design. The outcome measures were AW-related readmission, 30-day readmission and multiple readmissions. In 2013, 393,118 discharges involved ICD-9 coding for AW and 41.5% of these included AW as the primary discharge diagnosis. The rate of AW-related readmission in 2013, as estimated from first-quarter index events, was 58.8% (95% confidence interval (CI) 57.5–60.1), with an average of 1.8 readmissions (95% CI 1.7–1.9). The 30-day readmission rate, estimated from January–November index events, was 19.7% (95% CI 19.0–20.4). The strongest independent predictors of yearly, 30-day and multiple readmission were discharged AMA and comorbid psychotic disorder. AW readmission within 30 days and multiple readmissions during the year were common and were particularly predicted by AMA discharge and comorbid psychotic disorder. While these and other factors can help identify high-risk patients, further study to determine causal mechanisms may aid efforts to improve both the outcomes and costs associated with acute AW treatment.

28 October 2021 in American Journal of Infection Control
Verified
Journal Article
Open access
RKRenuka Ananth Kalyan Kadali
Renuka Ananth Kalyan Kadali
RJRavali Janagama
Ravali Janagama
SYSiva H. Yedlapati
Siva H. Yedlapati
NKNeelakanta Kanike
Neelakanta Kanike
VGViswanath Gajula
Viswanath Gajula
ISIsha Shah
Isha Shah
There are concerns regarding immunogenicity with coronavirus disease 2019 (COVID-19) mRNA vaccines among persons with prior history of COVID-19 (PHC). This study was to analyze the short-term side effects of mRNA vaccines among health care workers (HCWs) with and without PHC. A cross-sectional study was performed using an independent online survey questionnaire that gathered responses from HCWs. Among 1,475 HCWs, 1268 (85.97%) completed the survey, 102/1268 (44/447 in Moderna group and 58/821 in Pfizer-BioNTech group) reported PHC during pre-vaccination period. Symptoms of flushing/P = .05, brain fogging/P= .005, vertigo/P= .041, numbness/P= .023, diarrhea/P= .047, hives/P= .028, itching/P= .028, swelling of lips/mouth/P= .001, shortness of breath/P= .022, and anxiety/P= .048 have greater occurrence among Pfizer-BioNtech group with PHC when compared to Pfizer-BioNtech group with no PHC. Symptoms of chills/P= .027, flushing/P= .045, tremor/P= .05, muscle spasm/P= .039, vomiting/P= .031, diarrhea/P= .015, and cough/P= .011 have higher occurrence among Moderna group with PHC when compared to Moderna group with no PHC. Few short-term side effects among mRNA vaccine recipients with PHC may have necessitated transient time-off from work. The PHC can be considered as a predictor for severity of side effects. While the vaccination program continues in the United States, a future COVID legislation that mandates vaccination among employees along with paid time off provision may help with higher compliance and acceptance.

4 April 2016 in Journal of Hospital Medicine
Verified
Journal Article
Closed access
PDF file
SYSiva Harsha Yedlapati
Siva Harsha Yedlapati
AMAnuradha Mendu
Anuradha Mendu
SSScott H. Stewart
Scott H. Stewart

1 November 2012 in Journal of the American Society of Hypertension
Verified
Journal Article
Closed access
JJJoseph L. Izzo Jr.
Joseph L. Izzo Jr.
SYSiva H. Yedlapati
Siva H. Yedlapati
SFSheikh M. Faheem
Sheikh M. Faheem
UYUsman Younus
Usman Younus
POPeter J. Osmond
Peter J. Osmond

17 November 2020 in Circulation
Verified
Journal Article
Closed access
SYSiva Harsha Yedlapati
Siva Harsha Yedlapati
SKSafi U Khan
Safi U Khan
STSwapna Talluri
Swapna Talluri
ALAhmad Naeem Lone
Ahmad Naeem Lone
MKMuhammad Khan
Muhammad Khan
EMErin D Michos
Erin D Michos
Introduction: Influenza infection is associated with increased morbidity and mortality in patients with cardiovascular disease (CVD). We assessed the effects of influenza vaccine on mortality and cardiovascular outcomes in patients with CVD. Hypothesis: Influenza vaccination in those with CVD is associated with a reduction in mortality and major adverse cardiovascular events (MACE). Methods: We searched PubMed, EMBASE, and Cochrane library through January 2020 for randomized-controlled trials (RCTs) and observational studies assessing effects of influenza vaccine on mortality and cardiovascular outcomes in patients with CVD. Estimates were reported as random effects risk ratios (RR) with 95% confidence intervals (CI). Analyses were stratified by study design into RCT and observational studies. Results: Overall, 16 studies (n=237,058) encompassing 4 RCTs (n=1,667) and 12 observational studies (n=235,391) were included. The mean age was 69.2±7.01; 36.6% were female, 65.1% had hypertension, 31.1% had diabetes, and 23.4% were smokers. The median follow-up duration was 19.5 (IQR, 12, 43.3) months. Influenza vaccine was associated with a lower risk of all-cause mortality (RR, 0.72 [95% CI, 0.59-0.89], p<0.001) (Figure 1A), cardiovascular mortality (RR, 0.82 [95% CI, 0.80-0.84], p<0.001), and MACE (RR, 0.87 [95% CI, 0.80-0.94], p<0.001) (Figure 1B), though the association with myocardial infarction was not statistically significant (RR, 0.73 [95% CI, 0.50-1.07]; p=0.10). These finding were consistent across randomized and observational studies. Conclusions: This meta-analysis suggests that both randomized and observational data support the use of influenza vaccine in adults with CVD to reduce mortality and MACE events. Efforts to improve utilization of influenza vaccine in this population should continue to reap survival benefits. Download figure